Dublin-listed pharmaceutical services company Open Orphan has signed a new contract with a Japanese group which it expects will generate “significant revenue” for subsidiary Venn Life Sciences over the next year.
Open Orphan, a European-focused, rare and orphan drug consulting services platform, said on Tuesday the contract with Carna Bioscience was for a first in human clinical pharmacology trials.
Open Orphan is the result of executive chairman Cathal Friel reversing his pharma services business of the same name into Dublin-listed drug clinical trials manager Venn Life Sciences last year.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).